Last updated on January 2014

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects


Brief description of study

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

Detailed Study Description

A randomized, double-blind, superiority, multiple dose, placebo-controlled, parallel group, multi-centre, field study.

A minimum of 1182 subjects will be randomized into the study, 394 in each of 2 active treatment groups and placebo group, at a ratio of 1:1:1. Subjects will be stratified in each of the treatment groups according to asthma status and according to age, such that a target of 20%-30% of subjects are adolescent (12-17 years) and 70%-80% of subjects are adults (18-65 years). Subjects who withdraw may be replaced.

Subjects aged 12-65 years, with a documented history of moderate to severe allergic rhinoconjunctivitis only or allergic rhinoconjunctivitis plus GINA Step 1 controlled asthma on exposure to cats for at least 2 years.

Clinical Study Identifier: TX137586

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.